Compounds / Semaglutide

Semaglutide

Also known as: Ozempic, Wegovy, Rybelsus (brands)

Established human clinical FDA-approved (brand products) Category: GLP-1 and Metabolic

The compounds described in this library are research-use-labeled chemicals and are not FDA-approved for human use. This content is factual scientific reference drawn from published literature. It is not medical, dosing, or purchasing advice. VialReport does not sell, supply, or distribute any compound.

Short summary

A GLP-1 receptor agonist developed by Novo Nordisk and approved by the FDA under several brand names for type 2 diabetes and for chronic weight management. It has one of the largest clinical evidence bases of any compound in this library.

Dive deeper

Origin and Development

Developed by Novo Nordisk as a long-acting analogue of glucagon-like peptide-1, a naturally occurring incretin hormone. Structural modifications, including fatty-acid acylation, extend its half-life sufficiently for once-weekly subcutaneous dosing.

Mechanism as Understood in the Literature

Agonist at the GLP-1 receptor. GLP-1 signaling influences glucose-dependent insulin secretion, gastric emptying, and central appetite regulation.

Research Status

Extensive. Multiple large randomized controlled trials across type 2 diabetes, obesity, and cardiovascular outcomes, published in major peer-reviewed journals and forming the basis of its regulatory approvals. This is a fully developed pharmaceutical with a conventional evidence base, which distinguishes it sharply from most compounds in this library.

Regulatory status · approved

FDA-approved as a prescription medicine under several brand names.

Approved indications and formulations differ by brand.

Material sold outside the approved supply chain is not the approved product, regardless of how it is labeled.

Commonly Confused With

Frequently confused with tirzepatide, which is a different molecule with a dual GIP/GLP-1 mechanism, and with compounded or research-labeled semaglutide, which is not the FDA-approved product.

How This Compound Is Marketed

Vendors in this market commonly market this compound for weight loss and appetite suppression. These are vendors’ marketing claims, not VialReport’s. VialReport does not verify, evaluate, or endorse them, and nothing on this page is medical, dosing, or purchasing advice or a recommendation to use any compound. See “Research status” above for what the published literature actually establishes.

Analytical Profile

A 31-amino-acid modified peptide with a C18 fatty diacid side chain, molecular weight approximately 4114 Da. The acylation makes the molecule distinctive analytically, and mass spectrometry is well suited to distinguishing it from related GLP-1 analogues.

Stability and Handling

Approved products are supplied as refrigerated solutions with defined in-use storage windows. Lyophilized material sold outside the approved supply chain will not carry the same characterization.

Key Literature

  1. 01 Wilding JPH, et al. Once-weekly semaglutide in adults with overweight or obesity. N Engl J Med. 2021;384:989-1002.
  2. 02 Marso SP, et al. Semaglutide and cardiovascular outcomes in patients with type 2 diabetes. N Engl J Med. 2016;375:1834-1844.

VialReport publishes factual reference information and independent test data. Nothing here is medical, dosing, or purchasing advice.

Published reports

Reports for Semaglutide

No reports for this compound yet.

Want a vendor’s version of this compound tested? Request it and we’ll notify you when a report publishes.

Request a test

Stay current

Get notified when new reports publish.

Free. We email when results are in, and nothing else.

Powered by MailerLite. No spam. Unsubscribe anytime.